Results 11 to 20 of about 196,511 (287)

An intuitionistic approach for the predictability of anti-angiogenic inhibitors in cancer diagnosis

Scientific Reports, 2023
Malignant cancer angiogenesis has historically attracted enormous scientific attention. Although angiogenesis is requisite for a child’s development and conducive to tissue homeostasis, it is deleterious when cancer lurks.
Syed Anas Ansar, Shruti Aggarwal, Swati Arya, Mohd. Anul Haq, Vikas Mittal, Fikreselam Gared   +5 more
doaj   +1 more source

Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan

Journal of Dental Sciences, 2021
Background/purpose: The prevalence of oral adverse events and dental treatments related complications during the molecular targeted drugs therapy remains unclear.
Shin-ichi Yamada, Hiroshi Kurita, Akira Tanaka, Masaru Miyata, Yoshinari Morimoto, Akira Yamaguchi, Souichi Yanamoto, Hiromasa Yoshikawa, Yutaka Imai   +8 more
doaj   +1 more source

Thalidomide is an inhibitor of angiogenesis. [PDF]

Proceedings of the National Academy of Sciences, 1994
Thalidomide is a potent teratogen causing dysmelia (stunted limb growth) in humans. We have demonstrated that orally administered thalidomide is an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay.
Michael S. Loughnan, Judah Folkman, Robert J. D'Amato, Evelyn Flynn   +3 more
openaire   +4 more sources

Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer

Zhongliu Fangzhi Yanjiu, 2021
Advanced triple-negative breast cancer(TNBC) has less treatments, shorter survival time and poorer prognosis than other subtypes of breast cancer. The rapid development of immunotherapy in recent years is expected to prolong the survival time of advanced
HUANG Shifen, LING Xiaoling
doaj   +1 more source

Study of endostatin, tumstatin and PEDF, the natural angiogenesis inhibitors, potential in avasculargenic therapy

Oftalʹmologiâ, 2014
Purpose: To evaluate the potential of endostatin, tumstatin and PEDF in avasculargenic therapy.Methods: The avasculargenic potential of the natural angiogenesis inhibitors was explored on the model of alkaline burn, attended with angiogenesis of cornea ...
V. G. Likhvantseva, E. V. Arutyunyan, A. I. Miroshnikov, A. Yu. Salihov, O. V. Belous, K. D. Kurtshalidze, R. S. Esipov, K. A. Bejrahova,, V. N. Stepanenko   +8 more
doaj   +3 more sources

Normal Wound Healing and Tumor Angiogenesis as a Game of Competitive Inhibition. [PDF]

PLoS ONE, 2016
Both normal wound healing and tumor angiogenesis are mitigated by the sequential, carefully orchestrated release of growth stimulators and inhibitors.
Irina Kareva, Abdo Abou-Slaybi, Oliver Dodd, Olga Dashevsky, Giannoula Lakka Klement   +4 more
doaj   +1 more source

The Vasohibin Family

Pharmaceuticals, 2010
Angiogenesis is regulated by the local balance between angiogenesis stimulators and inhibitors. A number of endogenous angiogenesis inhibitors have been found in the body. The origin of these inhibitors is mostly extrinsic to the vasculature.
Yasufumi Sato
doaj   +1 more source

Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis

Journal of Hematology & Oncology, 2016
Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against the vascular endothelial growth factor (VEGF) or its receptors have been investigated in several studies for the treatment of advanced gastric cancer (GC). In the
Jing Yu, Yue Zhang, Lai-Han Leung, Lian Liu, Fan Yang, Xiaojun Yao   +5 more
doaj   +1 more source

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature

Frontiers in Cell and Developmental Biology, 2021
Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials.
Xi Zhang, Yang Liu, Zhen Zhang, Juan Tan, Junjun Zhang, Hao Ou, Jie Li, Zewen Song   +7 more
doaj   +1 more source

Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer – Narrowing the Gap Between Bench and Bedside

Frontiers in Immunology, 2022
Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been extensively investigated as a promising druggable biological process. Nonetheless, targeting angiogenesis has failed to impact overall survival (OS) in patients with mCRPC ...
Antonio Giovanni Solimando, Antonio Giovanni Solimando, Charis Kalogirou, Markus Krebs, Markus Krebs   +4 more
doaj   +1 more source